DNER and B-cell chronic lymphocytic leukemia: In this study, we characterized immunomodulatory effects of BET-i in preclinical models of CLL using OPN-51107, a pan-BET inhibitor in phase I/II trials (NCT04910152, NCT04022785; clinicaltrials.gov).